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Purpose: To evaluate the effectiveness of alcaftadine 0.05%, 0.1%, and 0.25% ophthalmic 
solutions in treating the signs and symptoms of allergic conjunctivitis when compared with 
olopatadine hydrochloride 0.1% and placebo using the conjunctival allergen challenge (CAC) 
model.
Methods: One hundred and seventy subjects were randomized and 164 subjects completed 
all visits. CAC was performed to determine and confirm subjects’ eligibility at visits 1 and 2, 
respectively. The CAC was repeated at visit 3 (day 0 ± 3), 16 hours after study medication instil-
lation, and at visit 4 (day 14 ± 3), 15 minutes after instillation. Ocular itching and conjunctival 
redness were evaluated after an allergen challenge, along with several secondary endpoints.
Results: Alcaftadine 0.25% and olopatadine 0.1% treatments exhibited significantly lower mean 
scores compared with placebo for ocular itching and conjunctival redness at visits 3 and 4. Most 
adverse events were self-limiting and mild in severity. No serious treatment-related adverse 
events occurred.
Conclusion: Treatment with alcaftadine 0.25% ophthalmic solution resulted in mean differences 
of .1 unit (ocular itching) and approximately .1 unit (conjunctival redness), which was 
significant (P , 0.001) compared with placebo treatment. All doses of alcaftadine were safe 
and well tolerated in the population studied.
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Introduction
Allergic conjunctivitis is an inflammatory condition that can be triggered by a variety of 
stimuli, including tree and grass pollens, animal hair or dander, and other environmental 
allergens. The most common and distressing ocular signs and symptoms associated with 
allergic conjunctivitis are redness (hyperemia) and itching (pruritus), respectively; other 
frequent signs include eyelid swelling (edema), swelling of the conjunctiva (chemosis), 
and tearing.1 The physiologic basis for allergies is multifactorial and involves both an 
early acute phase triggered by mast cell degranulation and release of histamine and 
a late phase involving various proinflammatory mediators including prostaglandins, 
leukotrienes, cytokines, and interleukins.2 The activation of H1 receptors found on 
conjunctival neurons by histamine released from mast cells is the cause of itching.3 
Histamine binding to H1 and H2 receptors on the vascular endothelium induces dilation 
(seen as redness) and endothelial swelling.1,4 H4 receptors widely expressed on immune 
and inflammatory cells also play a role in itching and inflammation.5–7Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Allergies are relatively common among the general 
population, affecting more than 15% of the global population 
and up to 30% of the US population, and the prevalence is 
increasing, probably due to environmental factors (pollution, 
pollen, air conditioning).1
Current treatments for allergic conjunctivitis include 
a variety of therapies from different classes of drugs, 
including antihistamine–vasoconstrictor combinations, 
antihistamine–mast cell stabilizers, corticosteroids, non-
steroidal anti-inflammatory drugs, antihistamines, and 
antihistamine–mast cell stabilizer combinations. Dual-
function agents (antihistamine, mast cell stabilization) have 
become the mainstay of pharmacologic therapy for ocular 
allergic disease; these therapies vary in potency, specificity, 
and duration of action, as demonstrated in varied dosing 
regimens.1
Alcaftadine (11-[1-methylpiperidin-4-ylidene]-6, 
11-dihydro-5H-imidazo [2, 1-b] [3] benzazepine-3-
carbaldehyde) is a new chemical entity developed as an 
antiallergic agent. Alcaftadine is a potent histamine H1, 
H2, and H4 receptor antagonist that has also demonstrated 
anti-inflammatory properties (unpublished data on file at 
Vistakon Pharmaceuticals, LLC, Jacksonville, FL, USA). 
Phase I safety studies of topically applied alcaftadine oph-
thalmic solutions have been completed and indicate that 
alcaftadine concentrations in the range of 0.05% to 0.25% 
are safe, well tolerated, and warrant further investigation for 
efficacy. Furthermore, alcaftadine has demonstrated protec-
tive characteristics relative to the induction phase of allergy; 
preclinical studies have shown it stabilized tight junction 
protein (zonula occludin-1) expressed in the conjunctival 
epithelium that normally becomes disorganized following 
allergen exposure (unpublished data on file at Vistakon 
Pharmaceuticals, LLC). In preclinical studies, the effects 
exhibited by alcaftadine, including a reduction in itching, 
redness, and eosinophil recruitment, accurately reflect 
the expected pharmacologic profile of a broad-spectrum 
antihistamine.1,4,5
This report describes the first clinical evaluation of the 
effectiveness of alcaftadine ophthalmic solution in treating 
the signs and symptoms of allergic conjunctivitis. Three 
concentrations of alcaftadine ophthalmic solution (0.05%, 
0.1%, and 0.25%) were compared with the vehicle of the 
alcaftadine ophthalmic solutions as a placebo control and 
with an active control (olopatadine hydrochloride ophthalmic 
solution, 0.1%) for effectiveness in alleviating the signs and 
symptoms of allergic conjunctivitis using the conjunctival 
allergen challenge (CAC) model.2,8
Materials and methods
study design
This was a prospective, single-center, double-masked, ran-
domized, active- and placebo-controlled CAC study. The 
study comprised four visits over a period of five weeks. 
The study was approved by an independent review board 
(IntegReview, Austin, TX, USA), and all procedures fol-
lowed the tenets of the Declaration of Helsinki and were 
consistent with Good Clinical Practices and applicable 
regulatory requirements. All subjects signed an independent 
review board-approved, written informed consent and Health 
Insurance Portability and Accountability Act form before 
commencement of the study procedures.
Inclusion and exclusion criteria included the following: 
subjects had to be at least 18 years of age; if female, have 
a negative pregnancy test at visit 1 and upon exit from the 
study; have a positive history of ocular allergies and/or a 
positive skin test reaction to specified allergens within the 
last 24 months; have a best-corrected visual acuity of 0.6 
logMAR or better in each eye, as measured using an Early 
Treatment Diabetic Retinopathy Study chart; and no wearing 
of contact lenses for at least three days prior to and during 
the study period. Subjects could not have any ocular or 
systemic condition that, in the opinion of the investigator, 
could affect the subject’s safety or trial parameters; manifest 
signs or symptoms of clinically active allergic conjunctivitis 
in either eye at the start of any visit; have undergone ocular 
surgical intervention within three months; have had a history 
of refractive surgery within six months; have used aspirin, 
aspirin-containing products, or H1-antagonist antihistamines 
within 72 hours; immunotherapeutic agents unless treatment 
had been maintained steadily for at least two months; corti-
costeroids or mast cell stabilizers within 14 days, any other 
topical ophthalmic preparations (including tear substitutes) 
other than the study drops within 72 hours; or an investiga-
tional drug or device within 30 days of the study; or to have 
been enrolled in another investigational drug or device study 
within 30 days.
Visits 1 and 2 were screening visits during which the 
CAC was conducted and subjects’ eligibility was assessed. 
At visit 1 (day -21), the allergen dose was titrated; a posi-
tive response was defined as a score of $2 on a 0–4 scale for 
both ocular itching and redness in at least two of the three 
vessel beds (conjunctival, episcleral, ciliary) at 10 minutes 
after an allergen challenge. Subjects were required to have 
a positive bilateral CAC reaction for at least two of the three 
time points for inclusion in the study. At visit 2 (day -14 ± 3), 
the CAC was repeated; eligibility criteria included a score of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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$2 for ocular itching, and a mean value of $2 for redness 
at 10 minutes after an allergen challenge to confirm the 
reproducibility of the allergic response.
At visit 3, eligible subjects were randomly assigned to one 
of the five treatment groups, ie, placebo, alcaftadine 0.05%, 
0.1%, or 0.25%, or active control (olopatadine hydrochloride 
ophthalmic solution, 0.1%, Alcon Laboratories Inc, Fort 
Worth, TX, USA). It should be noted that the alcaftadine 
0.25% ophthalmic solution tested in this study was not the 
final commercial formulation.
Sixteen hours following study medication instillation at visit 
3 (day 0 ± 3), a CAC was performed to assess duration of action. 
At visit 4 (day 14 ± 3), the CAC was repeated 15 minutes after 
study medication instillation to assess onset of action.
The primary endpoints were ocular itching (at visit 4, five 
minutes after an allergen challenge) and conjunctival redness (at 
visit 4, 15 minutes after a challenge). Itching was evaluated by 
the subject for each eye at minutes 3, 5, and 7 after a challenge 
at visits 3 and 4. Ratings were made on a scale of 0 (none) to 
4 (severe), allowing half-unit increments. Conjunctival redness 
was evaluated by the investigator for each eye at minutes 7, 15, 
and 20 after a challenge on the same scale. Secondary endpoints, 
assessed at minutes 7, 15, and 20 after a challenge, included cili-
ary and episcleral redness, chemosis, lid swelling, tearing, ocular 
mucous discharge, and nasal symptoms (sneezing, rhinorrhea, 
nasal congestion, nasal pruritus, and ear or palate pruritus). Nasal 
symptom composite scores were also calculated.
All adverse events, regardless of relationship to the study 
drug, were monitored and reported throughout the study. 
Adverse events were defined in the protocol and included 
any unfavorable or unintended sign or symptom observed 
by the physician or reported by the subject. In addition, 
standard ophthalmic examinations, logMAR visual acuity, 
and undilated funduscopy examinations were conducted as 
safety evaluations.
statistical methods
All efficacy analyses were performed on the intent-to-treat 
population, including all randomized subjects. Safety 
analyses were performed on the safety population, includ-
ing all randomized subjects who received study medica-
tion. The average scores from bilateral eyes for both ocular 
itching at the 5-minute postchallenge time point at visit 4 
and conjunctival redness at the 15-minute postchallenge 
time point at visit 4 were analyzed using a nonparametric 
Wilcoxon rank sum test. A particular dose level compared 
with placebo was considered statistically significant if both 
primary endpoints were significant at the α (two-sided) 1.7% 
level. All statistical comparisons for secondary efficacy 
endpoints were made at the α (two-sided) 5% level. The 
dose–response relationship was assessed using Spearman 
rank correlation and analyses of covariance for the primary 
variables at the corresponding visit and time point. For all 
tests, the average score of both eyes was used as the primary 
response variable.
Adverse events were coded by body system and pre-
ferred terms using the MedDRA Dictionary (Version 7.0). 
The number and percentage of subjects reporting any adverse 
events during the entire study were summarized for the three 
dose levels of alcaftadine and for placebo and olopatadine. 
The number and percentage of subjects reporting adverse 
events were also summarized by relationship to the study 
drug, as well as severity.
Results
The intent-to-treat population for this study consisted of 
all individuals who met the response criteria at visit 2 
described in the methods. Of the 170 subjects included 
following this visit, the mean score for ocular itching (five 
minutes after CAC) was 2.76; the mean values for each of 
the five treatment groups were 2.71, 2.74, 2.82, 2.72, and 
2.82. Scores exhibited a similar distribution for the redness 
measures at visit 2, and, as with the itching scores, there 
were no significant differences between scores for any of 
the groups established by randomization following visit 2. 
This result shows that the random distribution of subjects 
created five treatment groups with comparable allergic 
signs and symptoms as measured in the CAC model. Each 
of the groups (placebo, alcaftadine 0.05%, alcaftadine 
0.1%, alcaftadine 0.25%, olopatadine 0.1%) were randomly 
assigned 34 subjects, and of the 170 individuals in this 
intent-to-treat population, 164 subjects (96.5%) completed 
the study and six subjects (3.5%) discontinued. In general, 
the five treatment groups were evenly balanced with regard 
to demographics and baseline characteristics (Table 1).
CAC at 15 minutes after instillation  
of medication (onset of action)
All active treatment groups were clinically ($1 unit differ-
ence) and statistically (P , 0.001) superior to placebo at 
all time points for prevention of ocular itching (Figure 1, 
Table 2). Mean differences from placebo for alcaftadine 
0.25% were -1.95, -1.92, and -1.77 units at 3-, 5-, and 
7-minute post-CAC time points, respectively, whereas   
those for olopatadine were -1.89, -1.84, and -1.66, respec-
tively (Table 2).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The mean conjunctival redness scores for all active treat-
ment groups were lower than those of the placebo group 
at every postchallenge time point (Figure 2, Table 3). All 
concentrations of alcaftadine, as well as olopatadine, were 
statistically significantly different as compared with pla-
cebo in preventing redness at the first post-CAC evaluation   
(7 minutes), as were the alcaftadine 0.25% and olopatadine 
treatment groups at the 15- and 20-minute postchallenge 
time points. The difference in mean scores for olopatadine 
and alcaftadine 0.25% achieved clinical significance ($1 
unit difference) compared with placebo at one postchallenge 
time point (7 minutes), with -1.27 and -1.35 unit differences, 
respectively.
CAC 16 hours after instillation  
of medication (duration of action)
At the 16-hour post-CAC evaluation, all three alcaftadine 
concentrations produced lower mean ocular itching scores 
than both placebo and olopatadine (Figure 1, Table 2). All 
active treatment groups had clinically and statistically sig-
nificantly lower scores than placebo at all time points, with 
the exception of clinical significance for olopatadine at   
7 minutes postchallenge. At 7 minutes, the difference in the 
prevention of itching was statistically significant for alcaf-
tadine 0.25% versus olopatadine (P = 0.017).
Mean conjunctival redness scores were also lower for all 
alcaftadine treatment groups and the olopatadine treatment 
group compared with placebo at each time point. The alcaf-
tadine 0.25% and olopatadine treatment groups had statisti-
cally significantly lower mean scores at all postchallenge 
time points (Figure 2, Table 3). Moreover, only alcaftadine 
0.25% produced mean scores that were clinically signifi-
cantly lower than those of the placebo group: 1.00 and 1.01 
unit differences at 7 and 15 minutes post-CAC, respectively 
(Figure 2 , Table 3).
secondary endpoints
At both the 15-minute and 16-hour postinstillation evalua-
tions, both the alcaftadine 0.25% and olopatadine treatment 
groups exhibited statistically significantly lower mean scores 
than placebo for all secondary endpoints (ocular itching and 
conjunctival redness at all nonprimary endpoints, ciliary and 
episcleral redness, chemosis, lid swelling, tearing, ocular 
mucous discharge, and nasal symptoms) at every time point 
(P , 0.05). Ocular mucous discharge was noted only in one 
subject treated with alcaftadine 0.25% at 7 minutes after 
a challenge at the duration of action evaluation (visit 3). 
Table 1 Demographics
Placebo* Alcaftadine
0.05%
Alcaftadine
0.1%
Alcaftadine
0.25%
Olopatadine
0.1%
Total
n 34 34 34 34 34 170
Age, mean (sD) 38.9 (9.9) 44.7 (11.5) 44.5 (9.5) 41.0 (14.1) 38.5 (11.2) 41.5 (11.5)
Gender, n
Male (%) 13 (38.2) 9 (26.5) 15 (44.1) 13 (38.2) 15 (44.1) 65 (38.2)
Female (%) 21 (61.8) 25 (73.5) 19 (55.9) 21 (61.8) 19 (55.9) 105 (61.8)
race, n
Asian (%) 0 0 0 1 (2.9) 1 (2.9) 2 (1.2)
Black (%) 0 2 (5.9) 1 (2.9) 0 2 (5.9) 5 (2.9)
Caucasian (%) 33 (97.1) 31 (91.2) 32 (94.1) 32 (94.1) 30 (88.2) 158 (92.9)
Other 1 (2.9) 1 (2.9) 1 (2.9) 1 (2.9) 1 (2.9) 5 (2.9)
Note: *Placebo refers to the use of the vehicle of the alcaftadine ophthalmic solutions as placebo control.
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Alcaftadine 0.05% Alcaftadine 0.1% Alcaftadine 0.25% Olopatadine 0.1%
Onset of action CAC (visit 4) Duration of action CAC (visit 3)
7 min 5 min 3 min 7 min 5 min * *
*
Figure 1 Ocular itching scores at 3, 5, and 7 minutes postchallenge. Plots show the 
mean difference for each treatment group (treatment score – placebo score).
Note: *statistically significant difference from placebo (P , 0.05). On the left, data 
for onset of action, CAC 15 minutes after instillation. On the right, data for duration 
of action, CAC 16 hours after instillation.
Abbreviation: CAC, conjunctival allergen challenge.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Treatment with alcaftadine 0.25% consistently resulted in 
lower or equivalent scores than treatment with olopatadine.
Adverse events
The incidence of adverse events, including ocular 
adverse events or any adverse events related to the study 
medication, did not increase with increasing concentrations 
of alcaftadine. Only one subject (receiving alcaftadine 
0.25%) had a serious adverse event (dyspnea), which was 
unrelated to the study drug and caused early withdrawal 
from the study.
The ocular adverse events are listed in Table 4. All of 
these were self-limiting, resolved without treatment, and 
were graded as mild or moderate by the investigators. There 
were no ocular adverse events in the olopatadine group.
The most common nonocular adverse event was nasophar-
yngitis, reported in a total of six subjects (3.5%): one each in 
the placebo and alcaftadine 0.25% groups, and two each in 
the alcaftadine 0.05% and olopatadine groups. Dysgeusia, 
headache, and pharyngolaryngeal pain were reported in two 
subjects; otitis media, urinary tract infection, muscle spasms, 
dyspnea, nasal congestion, pruritus, rash, and skin irritation 
were each reported in one subject. In addition, no clinically 
significant changes were noted in visual acuity, ophthalmic 
examinations, or undilated funduscopy.
Discussion
The CAC model is a well established method used to evalu-
ate the efficacy of antiallergic medication.8 It was the piv-
otal study design used in the approval of all commercially 
marketed eye drops in the antihistamine–mast cell stabilizer 
drug class. The screening process during a CAC study 
ensures that all enrolled subjects demonstrate a reproducible 
moderate-to-severe allergic reaction. The primary efficacy 
variables generally assessed in CAC studies are ocular itching 
and conjunctival redness, the hallmark symptom and sign, 
respectively, of ocular allergy.
The active control used in this study was olopatadine 
hydrochloride ophthalmic solution 0.1% (Patanol®, Alcon 
Laboratories Inc). Olopatadine is the first dual-function antial-
lergic agent approved by the Food and Drug Administration 
(FDA) for the treatment of the signs and symptoms of allergic 
conjunctivitis. The recommended dose for olopatadine hydro-
chloride ophthalmic solution 0.1% is one drop two times per 
day at an interval of six to eight hours.9 Although not avail-
able at the time of the study, olopatadine 0.2% is indicated 
for itching alone and recommended for once-daily dosing. 
In comparison with olopatadine, the other dual-function 
(antihistamine, mast cell stabilizers) topical ophthalmic solu-
tions (ketotifen fumarate 0.025%, azelastine hydrochloride 
Table 2 Ocular itching scores compared with placebo
Time point  
post-CAC
Placebo Alcaftadine 0.05% Alcaftadine 0.1% Alcaftadine 0.25% Olopatadine 0.1%
Mean  
score
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference  
vs placebo
15-minute onset of action 
challenge (visit 4)
n = 33 n = 33* n = 33 n = 32 n = 33
  3 min 2.22 0.53 -1.69a,b 0.56 -1.66a,b 0.27 -1.95a,b 0.33 -1.89a,b
  5 min 2.33 0.72 -1.61a,b 0.60 -1.73a,b 0.41 -1.92a,b 0.49 -1.84a,b
  7 min 2.14 0.69 -1.45a,b 0.55 -1.59a,b 0.37 -1.77a,b 0.48 -1.66a,b
16-hour duration of action 
challenge (visit 3)
n = 34 n = 34 n = 34 n = 34 n = 34
  3 min 1.75 0.40 -1.35a,b 0.31 -1.44a,b 0.27 -1.48a,b 0.63 -1.12a,b
  5 min 1.88 0.52 -1.35a,b 0.47 -1.40a,b 0.40 -1.47a,b 0.79 -1.08a,b
  7 min 1.83 0.56 -1.27a,b 0.48 -1.35a,b 0.43 -1.40a,b 0.85 -0.99a
Notes: aSignificant mean difference from placebo (P , 0.05); bClinically significant ($1 unit) difference from placebo; *n = 32 at 7-minute time point.
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20 min
Alcaftadine 0.05% Alcaftadine 0.1% Alcaftadine 0.25% Olopatadine 0.1%
Onset of action CAC (visit 4) Duration of action CAC (visit 3)
15 min 7 min 20 min 15 min
**
Figure 2 Conjunctival redness scores at 7, 15, and 20 minutes postchallenge. Plots 
show the mean difference (treatment score – placebo score) for each group.
Note: *statistically significant difference from placebo (P , 0.05). On the left, data 
for onset of action, CAC 15 minutes after instillation. On the right, data for duration 
of action, CAC 16 hours after instillation.
Abbreviation: CAC, conjunctival allergen challenge.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 4 incidence of ocular adverse events
System organ class/ 
preferred terma
Placebo Alcaftadine Olopatadine Total
(n = 34)a 
n (%)
0.05%
(n = 34)a 
n (%)
0.10%
(n = 34)a 
n (%)
0.25%
(n = 34)a 
n (%)
0.1%
(n = 34)a 
n (%)
(N = 170)a 
n (%)
Ocular – right eye
Eye disorders
Abnormal sensation in eye 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Asthenopia 1 (2.9) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 2 (1.2)
Photophobia 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Visual acuity reduced 0 (0.0) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Totalb 1 (2.9) 1 (2.9) 0 (0.0) 3 (8.8) 0 (0.0) 5 (2.9)
General disorders and administration site conditions
Application site dryness 1 (2.9) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.2)
Application site paresthesia 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Application site pruritus 2 (5.9) 1 (2.9) 0 (0.0) 1 (2.9) 0 (0.0) 4 (2.4)
instillation site stinging 0 (0.0) 4 (11.8) 3 (8.8) 2 (5.9) 0 (0.0) 9 (5.3)
sensation of pressure 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Total 2 (5.9) 6 (17.6) 3 (8.8) 4 (11.8) 0 (0.0) 15 (8.8)
Ocular – left eye
Eye disorders
Abnormal sensation in eye 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Asthenopia 1 (2.9) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 2 (1.2)
Photophobia 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Totalb 1 (2.9) 0 (0.0) 0 (0.0) 3 (8.8) 0 (0.0) 4 (2.4)
General disorders and administration site conditions
Application site dryness 1 (2.9) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.2)
Application site paresthesia 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6)
Application site pruritus 2 (5.9) 1 (2.9) 0 (0.0) 1 (2.9) 0 (0.0) 4 (2.4)
instillation site stinging 0 (0.0) 3 (8.8) 3 (8.8) 2 (5.9) 0 (0.0) 8 (4.7)
sensation of pressure 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9) 0 (0.0) 1 (0.6)
Total 2 (5.9) 5 (14.7) 3 (8.8) 4 (11.8) 0 (0.0) 14 (8.2)
Notes: aMedDrA dictionary (version 7.0) is used for coding; bTotal includes subjects only once even if they had more than one adverse event in a body system or overall.
Table 3 Conjunctival redness scores compared with placebo
Time point  
post-CAC
Placebo Alcaftadine 0.05% Alcaftadine 0.1% Alcaftadine 0.25% Olopatadine 0.1%
Mean 
score
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference  
vs placebo
Mean 
score
Mean 
difference 
vs placebo
15-minute onset of action 
challenge (visit 4)
n = 33 n = 33 n = 33 n = 32 n = 33
  7 min 1.85 1.13 -0.72a 1.14 -0.70a 0.50 -1.35a,b 0.58 -1.27a,b
  15 min 1.96 1.62 -0.34 1.64 -0.32 1.02a -0.94 1.09 -0.87a
  20 min 1.80 1.67 -0.12 1.70 -0.10 1.06a -0.73 1.15 -0.64a
16-hour duration of action 
challenge (visit 3)
n = 34 n = 34 n = 34 n = 34 n = 34
  7 min 1.77 1.22 -0.55a 1.18 -0.59a 0.77 -1.0a,b 0.89 -0.88a
  15 min 2.02 1.55 -0.47 1.44 -0.58a 1.01 -1.01a,b 1.12 -0.9a
  20 min 1.91 1.58 -0.33 1.40 -0.51 0.99 -0.93a 0.99 -0.93a
Notes: aSignificant mean difference from placebo (P , 0.05); bClinically significant ($1 unit) difference from placebo.
0.05%, epinastine hydrochloride 0.05%) are indicated for 
the prevention of ocular itching only and recommended for 
twice-daily dosing.
The data presented in this report indicate that of all three 
alcaftadine ophthalmic solutions tested, alcaftadine 0.25% 
ophthalmic solution performed most effectively in preventing 
the signs and symptoms of allergic conjunctivitis. Alcaftadine 
0.25% was effective in reducing both ocular itching and con-
junctival redness at the onset of action and duration of action 
evaluations (CAC at 15 minutes and 16 hours following Clinical Ophthalmology
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administration of study medication, respectively). The onset 
of action data at visit 4 for alcaftadine 0.25% are superior to 
those for olopatadine 0.1%. Statistically significant results 
were observed for the prevention of signs and symptoms 
in both alcaftadine 0.25% and olopatadine 0.1% treatment 
groups when compared with placebo at the majority of onset 
and duration assessments.
The efficacy of alcaftadine 0.25% ophthalmic solution 
also appears to demonstrate persistency; only a 24% reduc-
tion in the mean difference from placebo in three-minute 
post-CAC itching was observed for alcaftadine 0.25% (1.95 
and 1.48 unit differences from placebo) between onset and 
duration assessments. These data also show that the effec-
tiveness of alcaftadine 0.25% detected at the 15-minute 
postdose CAC evaluation persists for at least 16 hours after 
instillation, raising the possibility for a once-daily recom-
mended dose administration regimen. Furthermore, the 
robust efficacy of alcaftadine 0.25% in preventing the signs 
and symptoms of allergic conjunctivitis 16 hours after a single 
dose may suggest a lasting protective mechanism. Although 
clinical research is required to confirm the preclinical zonula 
occludin-1stabilization in humans, this confirmation may 
substantiate the mechanism behind the long-lasting protec-
tion observed in the current study.
In conclusion, alcaftadine 0.25% ophthalmic solution was 
effective, showing superiority over placebo in preventing both 
the symptom of ocular itching and the sign of conjunctival 
redness of the CAC-induced allergic response. This effec-
tiveness was demonstrated at 15 minutes and 16 hours after 
instillation, indicating that alcaftadine 0.25% has a rapid 
onset of action and a substantial duration of action, making 
it a candidate for once-daily dosing for the prevention of itch-
ing due to allergic conjunctivitis. In July 2010, alcaftadine 
0.25% ophthalmic solution received FDA approval for the 
prevention of itching in the US.
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